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Introduction: Biosimilars, as defined by the European Medicines Agency, have been 
used in Europe since 2006. The landscape was considerably expanded when the first 
biosimilar of a monoclonal was approved and introduced in the European market. CT-
P13 was developed by Celltrion as an infliximab biosimilar in 2013, not without 
controversy. As these complex molecules cannot be completely identical, some experts, 
clinicians, and even patients were skeptical regarding the real bioequivalence of the 
drugs.  Currently, several new infliximab and adalimumab biosimilars are available or 
will reach the market in a few months 
Areas covered: Our goal is to review, mainly from a clinical perspective, the available 
evidence for bioequivalence of anti-TNF biosimilars. We aim to take into account not 
only preclinical studies, mostly done for regulatory issues, but also data from clinical 
studies.
Expert Opinion:  We can conclude that bioequivalence with originator is well 
demonstrated in those drugs which have followed European Medicines Agency 
regulatory pathways. Switching from originator to biosimilar appears safe for all 
indications. However, there are few data available for switching from one biosimilar to 
another, or for complete interchangeability. Prospective studies and strict 
pharmacovigilance are recommended. 
Keywords: infliximab, adalimumab, biosimilar, bioequivalence, switching, anti-TNF.
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1. INTRODUCTION 
Biological medicines (“biologicals”) contain active substances from biological source [1, 2]. 
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) 
defined a biosimilar medicine as a medicine “highly similar” to another biological medicine 
already marketed (“reference medicine”) in terms of structure, biological activity, clinical 
efficacy, safety and immunogenicity profile [1,3]. 
In 2018, a large wave of biosimilar is just starting, and by 2027, 77% of current biotech 
spending is expected to be subject to some form of competition. [2]. A large number of 
biosimilar medicines are in development and can be expected to reach the market in E.U and, 
may be, the U.S. by 2021 [4]. The introduction of biosimilars increases price competition, 
which affects not just the price of the respective reference products, but also the price of the 
whole product class. Price per treatment day (TD) of anti-TNF biosimilars in 2016 compared to 
price per TD of original products before biosimilar entrance were -13%. The three European 
countries where the highest price reduction of the total market were achieved in 2016 were 
Sweden, Norway and Denmark with -39%, -32% and -24% respectively. Biosimilars have the 
potential to improve patient access of the total market, for example Sweden has increased 
volume of anti-TNF in 2016 compared before biosimilar entrance to 74% and Slovakia intab 
93% [5].  
The impact of the introduction of biosimilars for infliximab (IFX) on inflammatory bowel 
diseases (IBD)-related health care costs has been estimated in the Netherlands. Compared with 
no introduction of biosimilar, cost savings over a total of 5 years were on average 9,850 € per 
Crohn´s disease (CD) patient and 2,250 € per ulcerative colitis (UC) patient [6]. 
A key point in the clinical development of biosimilars is demonstrating bioequivalence [7]. This 
review focus on anti-TNF biosimilars and bioequivalence studies to reference product. A 
systematic review of bioequivalence of anti-TNF biosimilars has been published [8], we add our 
perspective from a clinical point of view and the evidence emerging in the last two years. 
2. REGULATORY APPROVAL PROCESS 
Biological medicines are made by living organisms, which are naturally variable. Thus, the 
active substance in the final biological medicine can have an inherent degree of minor 
variability. This minor variability must fall within the acceptable range to ensure consistent 
safety and efficacy, and can be present within or between batches of the same biological 
medicine, particularly when manufacturing processes are modified during the commercial life of 
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the medicine [1]. EMA has pioneered in the regulation of biosimilars since the approval of the 
first one in 2006. The requirements for biosimilar approval in the US by FDA are based on the 
same scientific rationale as in the EU, although specific data requirements may differ between 
these two regions due to different legal framework [9]. Other international regulators such as 
Australia, directly apply the principles set out in the EU legislation [10]. The World Health 
Organisation (WHO) has developed its own guidelines for biosimilars and biosimilar 
monoclonal antibodies [11,12], with the aim of providing guidance to regulatory agencies 
worldwide. These WHO guidelines incorporate many of the scientific principles used by EMA. 
For this reason this review is going to focus on EU´s regulation.  Some of our data will not be 
globally valid, as in some countries regulations are different, and usually less stringent. 
Biosimilarity is demonstrated via comparability studies with the reference medicine [7]. 
Comparability is conceived as a step-wise process that is tailor-made for each product: 
- Comparative quality studies: in vitro studies compare the protein structure and 
biological function using sensitive techniques. These studies should be much more 
sensitive than clinical trials for detecting such differences.  
- Comparative non-clinical studies: these are pharmacodynamics studies in vitro. 
Pharmacodynamic studies in vivo (animal models) are only done if no suitable in vitro 
model exists. In vivo toxicological studies are only required in certain cases. 
- Comparative clinical studies: these studies are tailored to confirm biosimilarity and to 
address any questions that may remain form previous analytical or functional studies.  
As it has explained before, comparability is not a new concept. In most comparisons with the 
goal of demonstrating biosimilarity, only detailed analytical and functional in vitro tests are 
required. However, clinical trials may be needed if any impact on safety and efficacy is 
anticipated. This is particularly the case with very complex molecules, as monoclonal 
antibodies, in which is almost impossible to predict all the clinical consequences of a small 
variation in structure (eg glycosylation). 
The goal is to rule out potential product-related differences that could affect pharmacokinetics 
(PK), efficacy or safety, including immunogenicity. PK studies should be conducted in a 
homogeneous and sensitive population (healthy volunteers or patients) to detect any possible 
differences between the biosimilar and its reference medicine. To compare the pharmacological 
effects, a sensitive endpoint that allows detection of product-specific differences should be 
chosen. Equivalence margins are set specifically for the indication studied and depend on the 
endpoint chosen. They should represent the largest difference in efficacy that would not matter 
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in clinical practice, treatment differences within this range would thus be acceptable because 
they have no clinical relevance. These margins are not unique to biosimilar testing, they are 
routinely used in clinical trials.  
In EU, for the marketing authorisation procedure of biosimilar, the applicant should present a 
risk management plan/pharmacovigilance plan and a postmarketing safety monitoring is also 
required by FDA [1,9]. 
3. INFLIXIMAB AND ITS APPROVED BIOSIMILARS AGENTS  
IFX, marked as Remicade®, was the first anti-TNF used for treating IBD. Its biosimilars, CT-
P13 and SB2, were approved by the EMA and FDA for use across all indications of IFX. Other 
biosimilar products are in development. Due to the large amount of existing data, we will focus 
on the preclinical and clinical studies of the two-IFX biosimilars approved by EMA and FDA 
(CT-P13 and SB2). ( See Table 1) 
3.1 PRECLINICAL EVALUATION OF CT-P13 AND SB2 
CT-P13 has been the first biosimilar agent of IFX and has been the first biosimilar monoclonal 
antibody evaluated by EMA.  CT-P13 has the same amino acid sequence, is produced by the 
same type of cell line and has an identical pharmaceutical form, composition, route of 
administration and dosing regimen as the reference IFX. It has demonstrated identical primary 
and higher order structures than IFX. In terms of charge isoform, it has been observed to contain 
slightly less basic variants than the original product, the difference was shown to be largely due 
to the presence of C-terminal lysine, but it has shown no effect on the biological potency or 
safety of CT-P13 [13].  
All major physicochemical characteristics and biological activities of CT-P13 were comparable 
to those of Remicade®. The fermentation, purification of the active substance were adequate. 
The manufacturing process was satisfactorily validated and quality of the finished product was 
assured. CT-P13 exhibits a lower level of afucosylated glycans than Remicade®, hence a lower 
binding affinity to Fc?RIIIa and a lower binding affinity towards specific Fc receptors and a 
lower ex vivo in the most sensitive antibody-dependent cellular cytotoxicity (ADCC). However, 
no difference could be detected in several experiments that are more representative of 
pathophysiological conditions, and therefore more relevant clinically. All major 
physicochemical characteristics and biological activities of CT-P13 were comparable to those of 
Remicade® [14-16]. 
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The nonclinical studies CT-P13 versus Remicade® included PD, PK and toxicological studies. 
The nonclinical data consisted in several in vitro primary PD studies (including a human tissue 
cross reactivity study comparing biosimilar and original molecule), two pivotal toxicological 
studies (one with toxicokinetics and immunogenicity testing) and one PK study in order to 
compare the bioactivity profiles. The comparability was shown in the majority of parameters 
assessed. Some variability was seen in the results were acceptable, as difference observed in 
Fc?RIIIa binding, this observation does not impact in the biological activity and has no 
clinically relevant impact of the efficacy and safety of CT-P13 [14,15].  
SB-2 is developed and manufactured using Chinese hamster ovary cell (CHO) lines instead of 
the murine cell line that was used for the production of Remicade®. CHO is widely used for the 
manufacture of biotherapeutics [17,18]. The characterisation of SB-2 included a comprehensive 
battery of physicochemical and biological tests using sensitive and qualified analytical methods 
in order to elucidate the primary, secondary, and higher-order structure, post-translational 
modifications, glycosylation, charge variants, purity/impurities, and quantity and biological 
properties.
The relative content of C-terminus with Lys for Flixabi® was much lower than that of 
Remicade®, this was explained by the use of CHO cells. Heterogeneity of C-terminal residues is 
a characteristic of therapeutic monoclonal antibodies (mAbs), but C-terminal Lys variation does 
not impact PK profiles and did not impact on TNF-? binding activity [17]. 
Minor differences were observed in glycosylation pattern (manose and afucose), there was 
carried out a thorough investigation to support that these changes do not have any clinical 
relevant impact. The slightly higher Fc?RIIb and Fc?RIIIa binding Flixabi® compared to 
Remicade® did not translate into any difference in the relevant biological activity and is 
therefore concluded to be without impact on safety/efficacy. Additional biological assays were 
performed to further justify the observed binding difference of Fc?RIIIa using various 
conditions, and to evaluate the in vitro IBD model in order to support extrapolation of 
indication. The results of the assays indicate that under these conditions the differences are 
diminished [17]. 
Terminal sugars of Fc glycans have been shown to be critical for efficacy because Fc glycans 
influence Fc?RIIIa binding and subsequent ADCC activity. Combined percentages of 
afucosylated and high mannosylated glycans are positively correlated with Fc?RIIIa binding and 
ADCC in NK92-CD16, while no correlation is observed with the physiologically relevant 
PBMC (peripheral blood mononuclear cells). Differences in glycosylation could still have some 
biological impact that might be of interest in later clinical differences [19]. 
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Nonclinical studies included a series of in vitro and in vivo studies to demonstrate PD and PK 
and immunogenic similarities. Similar PK parameters were observed (rat and mice studies). PD 
studies supported biosimilarity between SB2 and Remicade® as all results were within the 
similarity range, with the exception of Fc?RIIIa (V/V type), Fc?RIIb, and FcRn binding assays. 
However, the difference was within assay variability for Fc?RIIb and FcRn binding assays, and 
binding activity differences in Fc?RIIIa (V/V type) and Fc?RIIb were not translated into ADCC 
activity since the ADCC activity of SB2 was within the similarity range. FcRn is known to 
internalise antibodies into cellular endosomes to protect antibodies from proteolysis and thus 
plays a role in prolonging half-life of serum IgG. Nevertheless, despite the small deviations 
outside the similarity margin in FcRn binding activity, these were not translated into PK 
differences [17,18,20]. 
A higher incidence of anti-drug antibody (ADA) in Flixabi® was found compared to Remicade®,
so the impact of the differences on the immunogenicity of Flixabi® was discussed in depth. It 
was concluded that the differences in quality attributes are unlikely to induce higher ADA 
incidence. Studies showed no differences in epitopes or antibody recognition sites between 
Flixabi® and Remicade® [17]. 
3.2 CLINICAL EVALUATION OF CT-P13 AND SB2 
CT-P13 
Regulatory approval of the IFX biosimilar CT-P13 was based on 2 randomized controlled trials 
comparing it with its originator product in rheumatic disease: the PLANETAS study in patients 
with ankylosing spondylitis (AS) [21] and the PLANETRA study in patients with rheumatoid 
arthritis (RA) [22]. Moreover, PLANETAS and PLANETRA extension studies that evaluate the 
long-term efficacy and safety of extended CT-P13 treatment over 2 years have recently 
published [23-25]. See Table 2 
The PLANETAS trial, was a phase I randomized, double-blind, parallel-group study that 
included 250 anti-TNF-naïve patients with active AS [21]. Patients were randomized to receive 
CT-P13 or IFX dosed at 5 mg/kg at weeks 0, 2 and 6 and then every 8 weeks up to week 30. 
The primary endpoint of the trial was to demonstrated PK equivalence at steady state [area 
under the concentration-time curve (AUC) and observed maximum serum concentration (Cmax)] 
between biosimilar and reference product evaluated between weeks 22 and 30. Steady-state PK 
was show to be equivalent for CT-P13 and IFX. PLANETAS trial also showed that efficacy, 
assessed at weeks 14 and 30 and that included several clinical index and clinical criteria, was 
highly similar between the two groups. The Assessment in Ankylosing Spondylitis Response 
Criteria (ASAS) 20 and the ASAS40 refer to a 20% and 40% improvement, respectively, in a 
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set of clinically relevant measures of AS activity.  At week 30, the odds ratio (biosimilar/IFX) 
for the ASAS20 and ASAS40 were 0.91 (95%CI, 0.51 to 1.62) and 1.19 (95%CI 0.70 to 2.00), 
respectively. Similar findings were obtained at other time points. These efficacy rates were 
comparable to those reported previously in pivotal trials of IFX in AS. Partial remission rates, 
adverse events and pharmacokinetics profiles for both products remained equivalent at week 54. 
In the subsequent open label PLANETAS extension study (n=174), 86 patients treated with IFX 
were switched to CT-P13 at week 54 and followed for 48 weeks more and 88 patients with CT-
P13 continued with biosimilar [23]. Efficacy endpoints at weeks 78 and 102 were all of them 
equivalent between the maintenance and switch groups.  The proportion of treatment-emergent 
adverse events seemed to be slightly higher in patients switching therapy than in patients 
continuously treated with CT-P13 (71.4% vs. 48.9%).  However, there were no notable 
differences between the maintenance and switch groups in the incidence of adverse events 
leading to treatment discontinuation. 
Positive results of PLANETAS trial prompted Celltrion to conduct the PLANETRA trial, a 
phase III randomized, double-blind, parallel-group study that included patients with active RA 
despite treatment with methotrexate (? 3 months) and received a stable dose (12.5-25 mg/week) 
for ? 4 weeks before screening [22]. Patients were randomized to CT-P13 (n=302) or IFX 
(n=304) with methotrexate and folic acid. The primary endpoint [the American College of 
Rheumatology 20% (ARC20) response at week 30] was similar for both groups (60.9% for CT-
P13 and 58.6% for IFX, 95%CI -6% to 10%). Other clinical disease activity indices, quality of 
life and all other PK and pharmacodynamics parameters were also highly similar in both groups. 
Regarding safety, incidence of drug-related adverse events also were equivalent. Of the 606 
patients included in PLANETRA study, 455 (CT-P13:233 and IFX:222) were treated up to 
week 54.  In this week, the ACR 20 response rate (CTP-13 74.7% vs IFX 71.3%), remission, 
pharmacokinetics profile and adverse events rates were also comparable between both groups 
[24]. Three hundred two patients of 455 who completed the PLANETRA study were enrolled in 
the open-label, single-arm extension study. All patients received every 8 weeks CT- P13 and 
concomitant methotrexate from weeks 62 to 102. Of these, 158 had received CT-P13 
(maintenance group) and 144 IFX (switch group) previously. At week 102, clinical efficacy and 
adverse events rate were similar in both groups (maintenance vs switch) [25].  
SB2 
Regulatory approval of the biosimilar SB2 was based on two pivotal studies published in 2015 
that compared it with Remicade®; a phase I randomized, single-blind, three arm, parallel group 
study in 159 healthy subjects [26] and a phase III, randomised, double-blind, parallel group 
study in patients with moderate to severe RA despite methotrexate [27].  
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In the phase I study, all patients received a single dose of 5 mg/kg of one of three IFX study 
drugs (SB2, EU-IFX or US-IFX) and then were observed for 10 weeks.  The primary PK 
parameters that were studied were AUC from time zero to infinity (AUCinf), AUC from time 
zero to the last quantifiable concentration (AUClast) and Cmax. Bioequivalence was to be 
concluded if the 90 % CIs for the ratio of geometric least squares means (LSMeans) of the 
treatments compared were completely contained within the pre-defined equivalence margin 
(0.8–1.25). In this clinical study, SB2 showed pharmacokinectic equivalent with its marketed 
reference products of IFX (EU-IFX and US-IFX). Moreover, no significant difference in terms 
of safety and immunogenicity profiles was found across the treatment groups [26]. 
In the phase III study, 584 patients were randomised in a 1:1 ratio to receive SB2 or IFX.  In 
2017,  results of study at week 30 were published [27]. The ACR20 response at week 30 was 
64.1% in SB2 vs. 66.0% in IFX. The adjusted rate difference was -1.88% (95% CI -10.26% to 
6.51%), which was within the predefined equivalence margin. The adverse event rate was 
comparable. Also in 2017, study results at week 54 were published [28]. The patient disposition 
was similar between the both groups: 78.0% of the SB2 group and 76.8% of the IFX group 
completed the 54 week study. We want to note that starting at week 30, stepwise dose 
increments by 1.5 mg/kg up to a maximum of 7.5 mg/kg were permitted at each visit if RA 
symptoms were not well controlled by the existing dose. This study showed that SB2 and IFX 
maintained comparability up to 54 weeks in all efficacy clinical outcomes measured. Indeed, the 
equivalence margin for the ACR20 rate difference, which was intended for the primary endpoint 
at week 30, was met also at week 54. In addition, efficacy related to dose increments, whether 
regarding frequency or final dose, was comparable between SB2 and IFX.  The safety profile 
was comparable up to 54 weeks, with no particular difference from the 30-week report.  
3.3 EXTRAPOLATION  
 
In IBD, after a stringent approval process, the EMA and the FDA authorized the CT-P3 and SB 
2 by “extrapolation” for all the therapeutic indications for which Remicade® was previously 
approved, as we mentioned previously.  
 
Extrapolation refers to the process of extending efficacy and safety data derived from one 
approved therapeutic indication for which the biosimilar has been demonstrated equivalence 
with reference medicinal product to other indications for which reference product is approved 
[7]. The approval of a biosimilar requires clinical data, as we mentioned previously, but clinical 
trials have a relatively minor role compared to their importance in the development and 
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approval of new drugs. It is important to know that biosimilar development programs do not 
want to demonstrate clinical efficacy of the product in a particular clinical indication, since it 
has been already done with the reference product. An important decision to be taken by de 
regulatory agencies is if to demand a confirmatory clinical trial for each indication, or to assume 
that extrapolation of indications is enough guarantee.  The EMA state in its most recent 
published guidelines that “Extrapolation of clinical efficacy and safety data to other indications 
of the reference monoclonal antibodies is possible based on the overall evidence of 
comparability provided from the comparability exercise and with adequate justification”, but 
not as an “automatic or systemic conclusion” [29]. In anti-TNF drugs, the EMA has included 
the mode of action of biosimilar in the “totality of evidence with adequate and relevant 
justification”.
For biological drugs that have several indications, the question arises as to which disease should 
be targeted in the pivotal clinical trial. The EMA establishes that the most sensitive disease 
should be selected for increasing the probability to detect any existing difference between 
products. But it is difficult to define which the most sensitive disease is. In the case of CT-P13, 
RA was selected for pivotal trial (PLANETRA study) [22], but it has claimed that IFX has a 
relatively low efficacy vs. placebo effect in this indication. Other aspects that may difficult 
extrapolation from AS and RA to IBD are lower IFX doses and the concomitant use of 
methotrexate in the III phase study. Moreover, RA and IBD have different clearance of IFX and 
different response to other monoclonal antibodies (for example: rituximab is effective in RA but 
not in IBD), suggesting the possibility of different mechanisms of inflammation.  
Despite the stringent approval process performed by regulatory agencies, extrapolation is one of 
most controversial issues regarding to biosimilars and finds some resistance in medical 
community [30-32]. Of course, regulatory agencies rules on pharmacovigilance for biosimilars 
are very strict because of the two trials required to authorise a biosimilar may not be sufficient 
to detect differences in the safety related to very infrequent adverse events.  Because of that, 
they require a very detailed risk management plan, even more important if extrapolation is 
approved. 
It is interesting to note that recently (2017), Kim Y. H, et al. presented in the 12th Congress of 
ECCO (European Crohn´s and Colitis Organisation), the first phase III randomised, double 
blind controlled trial that compares CT-P13 with IFX in patients with  IBD (active CD) [33]. 
They showed that the efficacy of CT-P13 was similar to IFX in terms of CD activity index-70 
(CDAI-70) (p-value= 0.5613), CDAI-100 (p-value= 0.7744)  and clinical remission (p-value= 
0.8329) up to week 6. 
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3.4 IMMUNOGENICITY  
Proteins and other biological medicines have an intrinsic ability to cause an unwanted immune 
response, which, in rare cases, could cause a serious adverse reaction or reduced efficacy. 
Formation of immune complexes between antidrug antibody and biologics (reference product 
and biosimilar) may increase frequency of infusion reactions, increase clearance, reduce serum 
biologic levels, reduce efficacy, and may have a more direct neutralizing effect on product 
target binding [32,34-36]. 
Immunogenicity may be influenced by many factors: product characteristics, treatment-related 
factors, patient or disease- related factors [32,34]. The proportion of patients who developed 
treatment-induced ADA varied widely across biologic/biosimilar agents, the incidence of ADA 
vary considerably across assay methods used and inflammatory disease states [34,36]. 
FDA mandate at least one clinical trial in which comparative immunogenicity of a biosimilar 
and its reference product is assessed, EMA has a specific “Guideline on immunogenicity 
assessment of monoclonal antibodies intended for in vivo clinical use” [9,37]. 
The frequency of neutralizing ADA has been similar between biosimilars and their reference 
products [35]. The proportion of patients positive for ADAs at week 54 in PLANETRA study 
was similar between the two groups: 41.1 % and 36.0 % with CT-P13 and RP, respectively. 
[24]. On the open label extension of PLANETRA study, switching CT-P13 in patients 
previously treated with reference product compared to continuing CT-P13 with AR, the 
proportion of patients with ADAs was similar between both groups at week 102 (p=0.48) [25]. 
See table 3 
Immunogenicity was also comparable between SB2 and reference product at 54 weeks [28], 
(p=0,270). At week 54, patients previously receiving IFX were randomised (1:1) to switch to 
SB2 or continuing SB2, up to week 70 [38], the incidence of ADA was comparable in the 
different treatments groups. Among patients who were negative for ADA up to week 54, newly 
developed ADAs were reported in 14.6%, 14.9% and 14.1% of the INF/SB2, INF/INF and 
SB2/SB2 groups, respectively. See table 3 
Patient who develops antibodies to a reference drug with resultant loss of clinical response 
should not be switched to its biosimilar. ADAs against IFX and CT-P13 in RA and in IBD 
patients has been shown equivalent immunogenicity with a similar antigenic profile for both 
IFX versions [39-41]. Findings in Fiorino`s study, in IBD patients, suggest that 
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immunodominant epitopes in the reference and CT-P13 drugs are equally present in SB2, all 
antibodies cross-react with any type of infliximab molecule. CT-P13 and SB2 could be 
interchangeable and will not lead to differences in ADA production [42]. 
3.5 SWITCHING 
Interchangeability and substitution between reference product to biosimilar are an open 
problem. According to the EMA, interchangeability is to change one medicine for another that 
is expected to achieve the same clinical result in a given clinical setting and in any patient, with 
the agreement of the prescribing physician. However, substitution is to dispense one drug 
instead of another interchangeable drug at pharmacy level, without consulting the prescriber. In 
general, automatic substitution of biosimilars is not recommended. The FDA determines that a 
biological product could be considered interchangeable to the referent product only if the 
biological product is biosimilar and if the expected clinical effects and the safety profile are the 
same in any given patient and if the risk to switch to biosimilar is not greater than the risk of 
continue with the originator product [43]. The FDA has the authority to say that a biosimilar is 
interchangeable and interchangeable product might be substituted for the reference product 
without the intervention of the prescribing physician [44].  
By now, only data regarding switch from infliximab to CT-P13 are available. As we have 
already mentioned, PLANETAS and PLANETRA extension studies showed similar efficacy 
and safety after the switch of IFX to CT-P13 and in those who had long-term CT-P13 treatment 
(102 weeks). Clinical efficacy, safety, and immunogenicity of switching between IFX originator 
and CT-P13 in IBD were evaluated in several studies [45-70] (see Table 4).  Most studies were 
retrospective, and only one was randomized (NOR-SWITCH trial) [71]. Gisbert et al. [43] in 
their recent systematic review, and after evaluated 24 studies, showed that disease control was 
confirmed in 1163 of the 1326 included patients. In the sub-analysis in function of type of the 
disease, the proportion of patients with CD that maintained disease control was 86% and with 
UC was 93%.   
NOR-SWITCH trial deserves special attention, because it is the only controlled and randomized 
study that evaluates switching [71]. This trial tested the interchangeability from IFX to CT-P13 
in patients with different disease: IBD, RA, AS, psoriasic arthritis and chronic plaque psoriasis. 
Patients included must be on stable treatment with Remicade® for at least 6 months and were 
randomized 1:1 to either continue IFX or switch to CT-P13. The study was designed as a non-
inferiority trial (prespecified non-inferiority margin of 15%). Finally, 481 patients were 
followed for 52 weeks. The authors did not observe significant increase in disease worsening 
between originator and biosimilar group. In particular, 155 patients with CD and 93 with UC 
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were included. Disease worsening was reported in 21.2% vs. 36.5% in originator and biosimilar 
CD group and in 9.1% vs. 11.9% in originator and CT-P13 UC group. Moreover, there were no 
differences in safety or immunogenicity. However, this study also has some design limitations 
and its results cannot yet be generalized to other biologicals medicines and their biosimilars.  
Finally, uncertainty remains of multiple switches back-and-forth between a reference medicine 
and its biosimilar or among multiple biosimilars [72]. We want to note that several ongoing 
studies will soon provide additional information of the clinical efficacy and safety of switching 
in patients with IBD (ClinicalTrials.gov :NCT02096861, NCT02998398 and “the SIMILAR 
Trial’’ NCT02452151). 
4 ADALIMUMAB AND ITS APPROVED BIOSIMILARS AGENTS 
There appear to be several “front runners” in the race to biosimilar adalimumab in Europe and 
United States. Leading the race are biotech major Amgen and Boehringer Ingelheim 
Pharmaceuticals. Other biosimilar products are in development (table 5). Due to the large 
amount of existing data we will focus on the preclinical and clinical studies of the two 
biosimilars of adalimumab approved by EMA and FDA (ABP 501 or BI 695501). 
4.1 PRECLINICAL EVALUATION   
ABP 501 is analytically similar, has the same primary amino acid sequence, similar structure 
and strength as the reference product. Comparative PD, PK and toxicology data demonstrate 
biosimilarity between ABP 501 and Humira®. [73,74]. A comprehensive assessment between 
ABP 501, adalimumab (USA) and adalimumab (EU) was conducted to demonstrate similarity in 
biofunctional activity. This included: testing of binding kinectis to TNF? and relative binding to 
transmembrane TNF?, the neutralizations of TNF?-induced caspase activation, TNF?- and 
lymphotoxin-?-induce chemokine production, cytotoxicity, binding to Fc-gamma receptors 
Fc?RIa, Fc?RIIa, Fc?RIIIa and FcRn, antibody-dependent cell-mediated cytotoxicity and 
complement-dependent cytotoxicity. Data demonstrate that ABP 501 is similar to both 
adalimumab (US and EU) with respect to biofunctional activities [75]. 
In a randomised, single-blind, single-dose, three-arm, parallel-group study, healthy subjects 
were randomised to received ABP 501 (n=67), adalimumab (US) (n=69) or adalimumab (EU) 
(n=67). The confidence interval (CI) for the geometrical mean ratio (GMR) of AUCinf and 
Cmax were within the prespecified standard PK equivalence criteria of 0,80 to 1.25 [76].  
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BI 695501 has demonstrated to be similar to adalimumab (US and EU). A comprehensive 
biosimilarity exercise has been performed (analysis of primary sequence, secondary and higher 
order structure, size, charge and hydrophobicity heterogeneity). Functional activity and antibody 
clearance was also demonstrated to be similar to adalimumab. The presence of foreign particles 
detected in some pre-filled syringe lots of BI 695501 was studied in depth, and potential safety 
issues arising from the presence of particles could be ruled out [77]. 
In 2016, a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-
PK) in healthy subjects was published. Its aim was to evaluate three-way pharmacokinetic 
similarity (bioequivalence), safety, and immunogenicity of BI 695501 compared with Humira® 
in healthy male subjects. Wynne et al.  included 327 patients who were randomized 1:1:1 to 
receive one 40-mg dose of BI 695501, US- or EU-approved Humira®. Bioequivalence between 
the three drugs was demonstrated with the 90% CIs of the ratios of all primary end points: C 
max, AUCinf and AUC from time zero to the last measurable concentration, being within the 
prespecified acceptance ranges of 80–125%. [78]. 
A phase II, 7-week, open-label study (VOLAIRTE® -RL) was conducted to examine 
administration of BI 695501 using autoinjector, showing a successfully self-administration after 
training [79]. 
4.2 CLINICAL EVALUATION OF ABP 501 or BI 695501 
At this time, there is no available clinical data regarding the efficacy of ABP 501 or BI 695501 
in IBD. See Table 2. 
ABP 501.  
Comparable efficacy and safety of ABP-501 to US-Humira® was assessed in 2 randomized, 
double-blind, phase III equivalence studies in patients with moderate to severe RA and in 
patients with moderate to severe plaque psoriasis.  
• The RA trial consisted of 526 patients treated with either ABP 501 (n=264) or US-
Humira® (n =262) every 2 weeks with concomitant methotrexate. The primary 
endpoint, ACR20 response at week 24, safety and immunogenicity were comparable 
between treatment groups [80].  
• In the psoriasis trial was included 350 patients treated with ABP 501 or with originator.  
175 patients were randomized to the ABP 501 arm. At week 16, half of the reference 
group was switched to ABP 501 and followed through week 52. Psoriasis Area and 
Severity Index percent improvements from baseline were similar across groups for 
weeks 16, 32 and 50 (range: 85·8-88·2%). Changes from baseline in percentage body 
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surface area affected were similar across groups and time points. Safety results were 
also comparable [81] 
BI 695501. 
VOLTAIRE-RA study was published in 2018. It is a randomised, double-blind, parallel-arm, 
58-week equivalence trial that compared efficacy, safety and immunogenicity of  BI 695501 and 
US-sourced Humira® in patients with moderate-to-severe RA on stable methotrexate treatment. 
Six hundred forty five  patients were randomised 1:1 to receive BI 695501 (n=324) or Humira®
(n=321) 40 mg subcutaneously for 24 weeks. At week 24, patients originally randomised to 
Humira® were re-randomised at week 24 to either continue Humira® (n=148) or switch to BI 
695501(n=147). There were no differences in the rate of treatment or trial discontinuation 
between treatment groups. The difference in the proportion of patients achieving an ACR20 
response was within the prespecified interval at week 12 and week 24 demonstrating therapeutic 
equivalence of both drugs. The analysis of the secondary efficacy endpoints supported the 
findings of the primary efficacy analysis. The mean percentage of patients meeting the 
ACR20/50/70 response criteria and the mean change from baseline in DAS28-ESR (Disease 
Activity Score in 28 joints using erythrocyte sedimentation rate) were similar in each treatment 
group at weeks 12 and 24 and across the switched and the continuous groups after re-
randomisation at week 48. BI 695501 and Humira® demonstrated also similar safety and 
tolerability [82]. 
5. CONCLUSIONS  
 
Biosimilars are here to stay, and most likely will be very important actors in the fields of 
rheumatology, dermatology, IBD, ophthalmology and, very specially, oncology. Quality, safety, 
and efficacy (at least for the clinically tested indications) are clearly warranted for the 
biosimilars of infliximab (CT-P13 and SB2) and adalimumab (ABP-501 and BI 695501) 
approved by EMA and FDA.  
6. EXPERT OPINION  
A. Biosimilars to antiTNF biologics approved by EMA and/or FDA have demonstrated 
bioequivalence in all available studies. 
Biologic drugs are complex molecules or even substances. Standard regulations for generics 
were not adequate, and all regulatory agencies have developed specific rules for approval of 
biosimilars.  EMA pioneered in 2006, and the task was apparently well done, as very few 
relevant incidents have occurred with different biosimilars in Europe. FDA, Australian, 
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Canadian, Japanese, and other regulatory agencies have released very similar regulations.  
Although when biosimilars to antiTNF antibodies were finally approved some doubts were 
raised in scientific societies, and patient’s associations, educational efforts and growing 
evidence have shown that EMA rules do a nice work in practice. Controlled and 
uncontrolled data from clinical trials and registers have shown that EMA biosimilarity 
nicely translates into clinical biosimilarity.
B. Immunogenicity of biosimilars has not been proven different to originators. In the 
particular case of CT-P13 immune response to the drug appears identical to originator in a 
number of very detailed studies 
The most controversial issue is that of immunogenicity, because in the case of monoclonal 
antibodies the extreme complexity of the molecule, very especially in glycosylation, makes 
theoretically possible a difference in epitopes. This could be particularly important as 
clinical experience with originators has demonstrated that immunogenicity is a key 
determinant of secondary failure to these biologic drugs.  In the case of CT-P13, the first 
released biosimilar to infliximab, there have been done very detailed studies with 
immunological and chemical techniques that have consistently demonstrated a complete 
immunologic similarity between the two infliximabs: in fact several serologic methods used 
in clinic for measuring infliximab levels cannot distinguish both molecules.  Clinical 
comparative trials have not shown any difference in immunogenicity between biosimilars 
and their reference products, and any immunological unexpected side-effect has been 
appeared when switching from originator to CT-P13. To date, no relevant differences have 
been shown   between biosimilars and their reference products. 
C. Switching from originator to biosimilars has been found to be safe and effective in several 
randomized trials and many prospective, observational studies 
Controlled clinical studies are very expensive, and as the differences between originator and 
biosimilar are expected to be few and difficult to find a high number of subjects needs to be 
observed to obtain significant statistically and clinically relevant conclusions. However, in 
all controlled studies biosimilars have shown complete bioequivalence to originators in all 
cases, according to predetermined criteria. Moreover, a great number of observational 
studies and data from national or regional registers have confirmed the same type of data. 
After switching from originator to biosimilar clinical efficacy has not changed and no new 
safety alert has been detected, in several pathologies and different countries. In fact, 
thousands of patients have been switched and no consistent problem has been identified to 
date.
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D. Multiple switching between different biosimilars and originator cannot be recommended 
with available data
However, it remains the possibility that as new biosimilars are compared to one originator, 
some differences (may be even important), could exist between two or more biosimilars.  
Probably, it would be prudent to avoid several changes in the same patient if there is no a 
very important reason. As more and more molecules reach the market, potential differences 
could be important. Multiple switching cannot be recommended with available data. We are 
expecting results from studies with several crossings of drugs in the same group of patients, 
but no data are available to date.  The wealth of data do not suggest that a really clinically 
significant problem will be detected in the future, but biology is so complex that we should 
be prudent. 
E. No unexpected safety issues have appeared after several years of biosimilars use in areas 
under reliable and strict regulations
The topic we are considering has very important economic issues. The conflicts of interest 
can be huge when billions of euros are on the table.  This should not be forgotten. So, it is 
very reassuring for us, as clinicians, that from 2006 the safety record of biosimilars in 
Europe is excellent. No severe unexpected adverse effect related with a biosimilar has been 
detected. This record suggests that EMA regulations are very well done, and if 
pharmacovigilance should remain a priority, we can be confident when prescribing 
biosimilars to our patients.  
F. Personal experience 
In our hospital we have been using several biosimilars from 2006, and soon after release we 
started using CT-P13 (Inflectra ®) for treating our patients with rheumatologic or digestive 
indications. In fact, we have direct experience in patients with Ulcerative Colitis and 
Crohn’s disease.  We have not been able to see any real difference between the biosimilar 
and the originator.  In fact, we have started all new treatments from 2015 with CT-P13, and 
we are progressively switching and have not noticed any unexpected problem.  
In our opinion, biosimilars approved by EMA are a good alternative for our patients, and do 
contribute to containing costs for the system.  Of course, if we think so one reason is we 
think bioequivalence has been clearly demonstrated by all methods: quality control, 
preclinical evaluation, controlled clinical trials, and a substantial quantity of observational 
data.
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ARTICLE HIGHLIGHTS BOX 
 
• Biosimilars to antiTNF biologics approved by EMA and/or FDA have demonstrated 
bioequivalence in all available studies. 
• Immunogenicity of biosimilars has not been proven different to originators.  
• Switching from originator to biosimilars has been found to be safe and effective in several 
studies
• Multiple switching between different biosimilars and originator cannot be recommended 
with available data 
• No unexpected safety issues have appeared after several years of biosimilars use  
• Biosimilars approved by EMA are a good alternative and do contribute to containing costs 
for the system 
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TABLES 
Table 1. Biosimilars and original product of infliximab authorised by EMA and FDA 
INFLIXIMAB EMA FDA 
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Tradename Company 
Date of 
authorisation 
Tradename Company 
Date of 
authorisation 
Original 
product 
Remicade® Janssen August 1999 Remicade® Centocor August 1998 
CT-P13 
Inflectra® Hospira-
Pfizer
September 
2013 
Inflectra® Celltrion April 2016 
Remsima® Celltrion September 
2013 
SB2 
Flixabi® Samsung 
Bioepis 
May 2016 Renflexis® Samsung 
Bioepis 
April 2017 
Zessly® Sandoz May 2018 
PF-
06438179 
Ixifi® Pfizer December 
2017 
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Table 2: Efficacy of infliximab and adalimumab biosimilar compared with reference products. Randomized controlled trials 
IFX BIOSIMILARS ADALIMUMAB BIOSIMILARS 
CTP13 vs.Reference IFX ABP 501 vs. reference adalimumab 
????????????????????
??????????????????????? ?????? ?????? ?????? ?????????????? ??????
??? ??????? ? ? ? ??? ???????  
CTP-13 (n=302) 60.9 5.1 16.6 ABP501 ( n=260) 74.6 
Reference IFX ( n=304) 58.6 34.2 15.5 Reference adalimumab (n=261) 72.4 
Tmt difference (%) [95 % CI] 2 (-6 to 10) NR NR RR of ACR20 ( 90% CI) 1.04 (0.95-1.13) 
??? ???????      
CTP-13 (n=302) 57.0 33.1 16.2   
Reference IFX ( n=304) 52.0 31.6 15.2   
???????????????????????????? ??????? ??????? ? ?????????????????????????????? ????? ?? ??????????
??? ??????? ? ? ? ??? ???????  
CTP-13 (n=115) 62.6 41.7  ABP501 ( n=260) 80.9 
Reference IFX ( n=122) 64.8 45.9  Reference adalimumab (n=261) 83.1 
OR ( 95%CI) 0.91 (0.53–1.54) 0.85 (0.51–1.42)  least-square mean difference (95%CI) -2.18 (-7.39 to 3.02) 
??? ???????      
CTP-13 (n=112) 70.5 51.8    
Reference IFX ( n=116) 72.4 47.4    
OR ( 95%CI) 0.91 (0.51–1.62) 1.19 (0.70–2.00)    
??? ???????      
CTP-13 (n=106) 67.0 54.7    
Reference IFX ( n=108) 69.4 49.1    
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OR ( 95%CI) 0.89 (0.50–1.59) 1.26 (0.73–2.15)    
SB2 vs.Reference IFX BI695501 vs. reference adalimumab 
???????????????????
???????????????????????????? ?????? ?????? ??????
?????????????????????????????
????????????????????????? ??????
??? ??????? ? ? ? ??? ???????  
SB2 (n=290) 55.5 30.7 15.5 BI695501 ( n=321) 67.0 
Reference IFX ( n=293) 59.0 33.8 17.1 Reference adalimumab (n=318) 61.1 
Tmt difference (%) [95 % CI] -2.95 ( -10.8 to 4.9) -2.53 (-10.07 to 5) -1.06 (-7.06 to 4.9)
Difference in proportions 
(BI 695501 – Humira, %) 90%CI 
5.9 ( -0.9 to 12.7) 
??? ??????? ? ? ? ??? ???????  
SB2 (n=302) 64.5 40.8 23.2 BI695501 ( n=321) 69.0 
Reference IFX ( n=304) 68.4 38.7 23.1 Reference adalimumab (n=318) 64.5 
Tmt difference (%) [95 % CI -3.34 ( -11.8 to 5.1) NR NR 
Difference in proportions 
(BI 695501 – Humira, %) 90%CI 4.5 ( -3.4 to 12.5) 
IFX: infliximab. RA: rheumatoid arthritis. ITT: intention to treat. ACR20: American College of Rheumatology 20%.  ACR50: American College of Rheumatology 50%.  ACR70: American College of Rheumatology 
70%.  AS: ankylosing spondylitis. ASAS: Ankylosing Spondylitis Response Criteria. PASI: Psoriasis Area and Severity Index. CI: confidence interval. 
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Table 3. Clinical trials evaluating antidrug antibody detected in patients in treatment with 
infliximab originator and biosimilars CT-P13 and SB2 
Proportion of patients 
positive for ADA 
First author Study Disease Week RP group BS group 
Yoo DH [24] Double blind. 
Compare RP to 
CT-P13  
RA in 
combination 
to MTX 
54 36.0 % 41.1 % 
Smolen JS 
[28] 
Double blind. 
Compare RP to 
SB2
RA in 
combination 
to MTX 
54 57.5 % 62.4 % 
Switch 
group 
BS group 
Yoo DH [25] Open-label 
extension. 
Compare 
switching from 
RP to CT-P13 to 
CT-P13  
RA in 
combination 
to MTX 
Switch group 
received RP 
for 54 weeks 
and BS until 
102 weeks. 
BS group 
received CT-
P13 for 102 
weeks 
44.8 % 40.3 % 
RP 
group 
Switch 
group 
BS 
group 
Smolen JS 
[38] 
Double blind. 
Compare 
switching from 
RP to SB2, to to 
RP to SB2 
RA in 
combination 
to MTX 
Switch group 
received RP 
for 54 weeks 
and BS until 
78 weeks. 
RP and BS 
groups 
received RP 
and BS for 78 
weeks 
50.5 % 
(after 
week 54 
14.9%)
45.7% 
(after 
week 54 
14.6%)
53.6% 
(after 
week 54 
14.1%)
RP: Reference Product; ADA: antidrug antibody; BS: Biosimilar; RA: rheumatoid arthritits; 
MTX: metotrexate 
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Table 4. Studies evaluating switching between infliximab originator and CT-P13.  
First Author Study design 
Sample size
( number of 
patients) 
Disease Control ( no disease 
worsening after switching) 
Arguelles-Arias 
[45,46] 
Prospective 74 86% at 6 months 
73% at 1 year 
Bettey [47] Prospective 134 93% 
Buer[48] Prospective 125 95% 
Díaz Hernández and 
Rodríguez Glez[49,50] 
Retrospective 72 100% at 6 months 
93% at 1 year 
Eberl [51] Prospective 62 100% 
Fiorino [52] Prospective 97 100% 
Guerrero Puente [53] Prospective 36 86% 
Hamanaka [54] Retrospective 3 100% 
Hlavaty [55] Retrospective 12 100% at 6 months 
75% at 1 year 
Jahnsen [56] Prospective 56 100% 
Jarzebicka [57] Retrospective 5 100% 
Jones [58] Prospective 71 76% 
Jung [59] Retrospective 36 86% 
Kang [60] Retrospective 9 89% 
Kang [61] Prospective 27 93% 
Kolar [62] Prospective 74 99% at 6 months 
100% at 1 year 
Nugent [63] Prospective 33 85% 
Park [64] Retrospective 46 87% 
Razanskaite [65] Prospective 143 80% at 6 months 
73% at 1 year 
Soret [66] Prospective 63 95%  
Sieczkowska [67] Prospective 22 100% 
Smits [68] Prospective 51 82% at 4 months 
Strik [69] Prospective 44 86% 
Suk [70] Retrospective 42 81% 
 
Table 5 Biosimilars and original product of adalimumab authorised by EMA and FDA 
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ADALIMUMAB EMA FDA 
Tradename Company 
Date of 
authorisation 
Tradename Company 
Date of 
authorisation 
Original 
product 
Humira Abbvie September 
2003 
Humira Abbvie December 
2002 
ABP 501 
Amgevita Amgen March 2017 Amjevita Amgen September 
2016 
Solymbic Amgen March 2017 
BI 695501 
Cyltezo Boehringer
Ingelheim 
November 
2017 
Cyltezo Boehringer
Ingelheim 
August 2017 
SB5 
Imraldi Samsung 
Bioepis 
August 2017 
GP2017 
Halimatoz 
Hefiya
Hyrimoz 
Sandoz 
Sandoz 
Sandoz 
July 2018 
July 2018 
July 2018 
Others molecules in vias of authorisation: M923, FKB327, TUR01, ZRC-3197, MSB11022 
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